FDA approves the first oral GLP-1 medication January 4, 2025 Summary: The FDA approved the first oral GLP-1 for weight loss, a high dose of semaglutide, and a second oral GLP-1, orforglipron, will likely be approved soon
High glucose levels lead to the creation of advanced glycation end products (AGEs), which contribute to fibrotic tissue formation [28], and both AGEs and excess insulin can promote fibroblast proliferation and ECM production [29,30]

INGREDIENTS: Cetyl Hexanoate, Silica S-30 Tetraoleate, Glycerin, Triethyl Hexanoate, Polyglyceryl-10 Diisostearate, Dipropylene Glycol, Diisostearyl Maleate, Caprylic/Capric Triglyceride, Sunflower Seed Oil, Glyceryl Behenate/Eicosadioate, Olive Oil, Jojoba Seed Oil, Stearoil Inulin, Lavender Oil, Lemon Peel Oil, Sea Buckthorn Fruit Oil, Polyglyceryl-10 Behenate/Eicosadioate, Philippine Orange Peel Oil, Atlas Cedarwood Oil, Caprylyl Glycol, Ethylhexylglycerin, Orange Peel Oil, Rosemary Leaf Oil, Purified Water, Candida Bombicola/Glucose/Methylrape Seed Fermentation Water, Tocopherol, 1,2-Hexanediol, Ascorbic Acid, Hydroxypropyl Cyclodextrin, Glutathione, Disodium EDTA, Niacinamide, Panthenol, Linoleic Acid, Biotin, Tocopheryl Acetate, Cyanocobalamin, Limonene, Linalool, Citral, Geraniol, Citronellol
The cryo-EM structure, resolved at approximately 3.0 angstroms, showed that orforglipron occupies a pocket within the TMD that is entirely distinct from the peptide-binding site
This will replace the medication youre taking out of the vial so you dont create a vacuum over time